Free Trial
NASDAQ:ACTU

Actuate Therapeutics (ACTU) Stock Price, News & Analysis

Actuate Therapeutics logo
$8.86 +0.28 (+3.26%)
(As of 10:46 AM ET)

About Actuate Therapeutics Stock (NASDAQ:ACTU)

Key Stats

Today's Range
$8.86
$8.86
50-Day Range
$5.80
$9.23
52-Week Range
$5.51
$10.16
Volume
2,208 shs
Average Volume
44,625 shs
Market Capitalization
$173.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Receive ACTU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Actuate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACTU Stock News Headlines

Tesla Execs are Freaking Out
It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.
Actuate Therapeutics Inc ACTU
See More Headlines

ACTU Stock Analysis - Frequently Asked Questions

Actuate Therapeutics' stock was trading at $8.61 on January 1st, 2024. Since then, ACTU shares have increased by 0.7% and is now trading at $8.67.
View the best growth stocks for 2024 here
.

Actuate Therapeutics (NASDAQ:ACTU) issued its quarterly earnings results on Tuesday, September, 24th. The company reported ($4.20) earnings per share (EPS) for the quarter.

Actuate Therapeutics (ACTU) raised $27 million in an initial public offering (IPO) on Tuesday, August 13th 2024. The company issued 3,000,000 shares at $8.00-$10.00 per share. Titan Partners served as the underwriter for the IPO and Newbridge Securities Corp. was co-manager.

Actuate Therapeutics' quiet period expired on Monday, September 23rd. Actuate Therapeutics had issued 2,800,000 shares in its initial public offering on August 13th. The total size of the offering was $22,400,000 based on an initial share price of $8.00. During Actuate Therapeutics' quiet period, underwriters and any insiders that worked on the IPO were prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Actuate Therapeutics' top institutional shareholders include Northwestern University (0.14%) and KG&L Capital Management LLC (0.06%). Insiders that own company stock include Equity Cof Lp Bios, Todd S Thomson and Leslie W Kreis.
View institutional ownership trends
.

Shares of ACTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Actuate Therapeutics investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Aileron Therapeutics (ALRN), Amgen (AMGN) and AstraZeneca (AZN).

Company Calendar

Last Earnings
9/24/2024
Today
11/20/2024
Next Earnings (Estimated)
12/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ACTU
Previous Symbol
NASDAQ:ACTU
Web
N/A
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$169.34 million
Optionable
N/A
Beta
N/A
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

This page (NASDAQ:ACTU) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners